Evaluating the effect of Agomelatine in patients with obstructive sleep apnea
Phase 3
- Conditions
- Obstructive sleep apnea.Obstructive sleep apnea (adult) (pediatric)G47.33
- Registration Number
- IRCT20151227025726N26
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Patients with age above 18 years old with obstructive sleep apnea that refer to the Sleep Clinic of Masih Daneshvari Hospital.
Exclusion Criteria
Pregnancy
Breastfeeding
Neurological disease (stroke, epilepsy, tumor, previously neurological manipulation)
Use of stimulant drugs
Allergy to Agomelatine or formulation components
Having stage 2 or 3 of liver failure
Ciprofloxacin consumption
Fluvoxamine consumption
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The assessment of polysomnography parameters. Timepoint: The assessment of polysomnography parameters 2 days after agomelatine consumption. Method of measurement: With measurement of recorded criteria in the polysomnography test response.
- Secondary Outcome Measures
Name Time Method